Vol. 43 (1): 36-46, January – February, 2017
Merve Aydin 1, Aliseydi Bozkurt 2, Aytekin Cikman 1, Baris Gulhan 1, Mehmet Karabakan 2, Aysun Gokce 3, Murat Alper 3, Murat Kara 1
1 Department of Medical Microbiology, Faculty of Medicine, Erzincan University, Erzincan, Turkey; 2 Department of Urology, Erzincan University, Mengucek Gazi Training and Research Hospital, Erzincan, Turkey; 3 Department of Pathology, Dıskapı Training and Research Hospital, Ankara, Turkey
Objectives: The aim of this study was to assess the possible role of HPV in the development of prostate cancer (PCa) and investigate the distribution of the p53 codon 72 polymorphism in PCa in a Turkish population.
Materials and methods: A total of 96 tissues, which had been obtained using a radical surgery method, formalin-fixed and parafin-embedded, were used in this study. The study group consisted of 60 PCa tissues (open radical prostatectomy) and the control group contained 36 benign prostatic hyperplasia tissues (BPH) (transvesical open prostatectomy). The presence of HPV and the p53 codon 72 polymorphism was investigated in both groups using real-time PCR and pyrosequencing.
Results: The results of the real-time PCR showed no HPV DNA in any of the 36 BPH tissue samples. HPV-DNA was positive in only 1 of the 60 PCa samples (1.7%). The HPV type of this sample was identified as HPV-57. The distribution of the three genotypes, Arg/Arg, Arg/Pro and Pro/Pro was found to be 45.6, 45.6, and 8.8% in the PCa group and 57.1%, 34.3% and 8.6% in the control group, respectively. Compared with the control group, patients with PCa had a higher frequency of the Arg/Pro genotype and Proline allele (odds ratio (OR)=1.67, 95% confidence interval (CI)=0.68-4.09, p=0.044; OR=1.13, 95% CI=0.76-1.68, p=0.021, respectively).
Conclusions: The results of the study do not support the hyphothesis that prostate cancer is associated with HPV infection but indicated that Proline allele can be a risk factor in the development of PCa in the Turkish population.
Keywords: Papillomaviridae; Prostatic Neoplasms; Tumor Suppressor Protein p53